Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

bone marrow. This is important because existing therapies often fail to effectively eliminate cancer cells in these tissue sites. Targeted therapy for CLL is becoming a reality, and this new approach may greatly improve the lives of patients with this disease."

The study also evaluated in vivo effects of ibrutinib using blood and tissue samples collected before and during treatment. Ibrutinib demonstrated rapid and sustained disease control in blood, lymph nodes, spleen and bone marrow. After 6 months, 95 percent of patients experienced a reduction in lymph node size and all showed reduction in spleen enlargement, with a median reduction of 55 percent. In 26 patients, for whom a bone marrow biopsy was done, tumor infiltration decreased by 82 percent.

The Progression Free Survival probability for these patients at 12 months was estimated to be 94 percent. Most adverse events were mild and manageable and included diarrhea, fatigue and rash, severe events occurred in less than 13 percent of patients. 

"We are very pleased with the continued research that is being demonstrated at AACR across 9 different presentations. These advances show the potential breadth of the ibrutinib program and provide further opportunities for us to pursue. We are grateful for the continued support of our collaborators, investigators, patients and shareholders," said Bob Duggan , CEO and chairman of the board.

Ibrutinib has been designated as a FDA Breakthrough Therapy in CLL patients with deletion 17p, based on data from completed Phase I/II clinical studies, where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease, and may provide a substantial improvement over existing therapies for this indication.

About Chronic Lymphocytic Leukemia

CLL is the most common type of leukemia, a cancer of the whi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 14, 2014  Invivotek L.L.C., a member of ... announce that its animal research facility was awarded ... and Accreditation of Laboratory Animal Care International (AAALAC). ... science worldwide through voluntary accreditation and assessment programs. ... and use in 38 countries. Invivotek ...
(Date:7/14/2014)... , July 14, 2014  Remedy Informatics, the ... healthcare delivery and life sciences research, announced that ... Foundation (NPF) to build the first-ever national patient ... cancer and pancreatitis. "The National Pancreas ... change that thoughtful and committed organizations can effect ...
(Date:7/14/2014)... SAN DIEGO , July 14, 2014  More than ... love their smartphones and tablet computers -- but their eyes ... humans have never needed before, and the eye has not ... lives and what our eyes can do comfortably often results ... symptoms collectively known as Digital Eye Strain. Now ZEISS has ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3
... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Wednesday, May 4. ... financial results and operating activities open to all interested parties ...
... 25, 2011 STAAR Surgical Company (NASDAQ: ... minimally invasive ophthalmic lenses for refractive surgery, today announced ... (ICL™) V4c design.  The V4c design incorporates a proprietary ... a size determined to optimize the flow of fluid ...
Cached Medicine Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 3Visian® ICL and Toric ICL V4c Receive CE Mark Approval 4
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the ... is a helpful guide that features a series of new ... in its review that this book can help readers understand ... of high blood pressure, and effective methods to control ... are reviewed now by Vkool, was penned by Ken Burge, ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... July 14, 2014 "Medical devices, tests, ... of us. The Tri-Valley is a star when it ... in the region are working on amazing products and ... face of medicine," according to Dale Kaye CEO of ... showcase some of the brilliant minds and businesses that ...
(Date:7/14/2014)... July 14, 2014 Reha Technology ... a compact, portable and full-featured upper extremity robotic ... use of interactive games and challenges in a ... Occupational Therapy , Armotion combines a ... order to maximize the therapy effect for patients ...
(Date:7/14/2014)... COPENHAGEN Participation in activities that promote mental ... may help protect against the development of Alzheimer,s ... new research reported today at the Alzheimer,s Association ... , Research reported at AAIC 2014 also showed ... post-traumatic stress disorder (PTSD) may increase dementia ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 2Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 3Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 4Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 5Health News:Potential Alzheimer's disease risk factor and risk reduction strategies become clearer 6
... Animal Dermatology Clinic,announces the grand opening of their ... in Pasadena, CA. The 3,700 square foot facility ... room, where laser,surgeries, allergy testing, biopsies, and other ... on-site, in a quiet and stress-free,environment. There is ...
... 31 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the "Company"), ... commercialization of novel antibiotics for the,treatment of antibiotic-resistant ... PhD, was honored last night by The,Connecticut Women,s ... & Induction,Ceremony. As part of this year,s event, ...
... International has,named John T. Kelly, M.D., Ph.D. as Chief ... to improve the health and,wellness of the users of ... "Our mission is to promote healthier lifestyles and ... "Dr. Kelly will,play a key role in our strategy. ...
... Stylish and Sophisticated, Life is Full of,Possibilities and ... Loss., PISCATAWAY, N.J., Oct. 31 Personalizing,solutions for ... Siemens Hearing,Instruments, Inc., a leading manufacturer of hearing ... announcing their new Life,hearing instruments at this year,s ...
... from strangers, expert says , , FRIDAY, Oct. 31 (HealthDay ... parents are wondering how they can help keep their ... of pediatric emergency services at Morgan Stanley Children,s Hospital ... make Halloween a happy and safe occasion for everyone. ...
... HOUSTON, Oct. 31 Cyberonics, Inc. (Nasdaq:,CYBX) ... Medicaid Services,(CMS) has published the 2009 CMS Outpatient ... Classification (APC) rate for VNS,Therapy. The final rule, ... at $12,545 for insertion of VNS Therapy generators ...
Cached Medicine News:Health News:Animal Dermatology Clinic Announces Today the Grand Opening of a State of the Art Veterinary Specialty Practice in Pasadena, California 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 2Health News:Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Women's Hall of Fame 3Health News:Lifeclinic Names Harvard Ph.D. as New Chief Medical Officer 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 2Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 3Health News:Siemens Introduces Life, an Open Fit Hearing Instrument That is Beautiful, Smart, and Discreet 4Health News:Family Halloween Safety Can Be Fiendishly Simple 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 2Health News:Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS 3
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Bipolar forceps...
... visualize the presence of Human Papilloma Virus (HPV)., ... sample types: tissue, monolayer-based preparations, and conventional Pap. ... The Family 16 probe cocktail has an affinity ... 39, 51, 52, 56, 58, and 66. The ...
... Common primary human fungal pathogens ... spp., opportunistic fungal pathogens, including ... cerevisiae, Acremonium, Coccidioides immitis, Histoplasma ... and Pneumocystis carinii. The (1-3)--D-glucan ...
Medicine Products: